checkAd
    Deciphera Pharmaceuticals Aktie
    25,28
     
    USD
    +72,56 %
    +10,63 USD
    Letzter Kurs 02:00:00 Nasdaq
    25,27
     
    USD
    1.200 STK
    Geldkurs 29.04.24
    25,28
     
    USD
    6.000 STK
    Briefkurs 29.04.24
    ISIN: US24344T1016 · WKN: A2H48H · SYM: DCPH · USA

    Neueste Nachrichten

    DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
    29.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
    29.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
    09.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
    27.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
    06.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
    01.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    01.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    18.01.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 18.01.2024
    18.01.24 · wO Chartvergleich · Cerus Corporation
    Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
    08.01.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
    05.01.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · Business Wire (engl.) · Deciphera Pharmaceuticals